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Available online 23 March 2016Tissue engineering is currently exploring new and exciting avenues for the repair of soft tissue and organ defects.
Adipose tissue engineering using the tissue engineering chamber (TEC) model has yielded promising results in an-
imals; however, to date, there have been no reports on the use of this device in humans. Five female post mastecto-
my patients ranging from 35 to 49 years old were recruited and a pedicled thoracodorsal artery perforator fat ﬂap
ranging from 6 to 50 ml was harvested, transposed onto the chest wall and covered by an acrylic perforated
dome-shaped chamber ranging from 140 to 350 cm3. Magnetic resonance evaluation was performed at three and
sixmonths after chamber implantation. Chamberswere removed at sixmonths and sampleswere obtained for his-
tological analysis. In one patient, newly formed tissue to a volume of 210mlwas generated inside the chamber. One
patient was unable to complete the trial and the other three failed to develop signiﬁcant enlargement of the original
fat ﬂap, which, at the time of chamber explantation, was encased in a thick ﬁbrous capsule. Our study provides ev-
idence that generation of large well-vascularized tissue engineered constructs using the TEC is feasible in humans.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Chamber1. Introduction
To “rob Peter to pay Paul”, has been the cornerstone of reconstruc-
tive surgery since its inception. From the earliest reports of tissue rear-
rangements to resurface cutaneous defects to the development of
sophisticated procedures based on sound anatomical knowledge and
meticulous surgical technique, soft tissue reconstruction has invariably
relied on ﬂap harvest and inset. In spite of the remarkable advances
witnessed during the last decades with regard to (micro)surgical tech-
nique and the description of new ﬂaps, donor site morbidity and com-
plications remain unresolved issues in tissue transfer (Mennie et al.,
2015). While the use of alloplastic implants and fat grafting overcome
donor-site-related problems, they also present some major drawbacks.
Implants offer a straightforward and relatively simple alternative withence Agenda.
nerative Surgery, St. Vincent's
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U
Vpen access article under the CC BY-Npotentially excellent results, but complications are not infrequent and
can sometimes bring devastating consequences. Fat grafting, on the
other hand, has gained increased popularity due to the relatively abun-
dant donor tissue, ease of the procedure and low morbidity. Neverthe-
less, the unpredictability of long-term graft retention and the need for
additional fat injections or stem cell enriched lipoaspirate to achieve
or maintain the desired volume remain a concern. (Zhou et al., 2016).
The prior application of a device generating an external traction force
(e.g. BRAVA ®) may improve the reliability of fat grafting by priming
the underlying tissues but such a technique is not yet widespread and
has not been described for reconstruction of soft tissue defects other
than breast (Khouri et al., 2014, 2015).
Tissue engineering has traditionally targeted the regeneration of tis-
sues and organs essentially through two approaches: 1) the fabrication
of tissues using scaffolds and cells ex vivo and their subsequent implan-
tation in vivo; and 2) the stimulation of tissue growth directly in vivo.
Through the scaffold approach, scientists and surgeons have achieved
important breakthroughs in the repair of a variety of tissues in humans,
including bone, bladder, nasal cartilages and trachea (Atala et al., 2006;
Raya-Rivera et al., 2014; Fulco et al., 2014; Olausson et al., 2012; HenkelC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Inclusion and exclusion criteria.
Inclusion criteria
• Female patient
• Previous excisional surgery for malignant, premalignant or benign breast disease
resulting in a deformity
• Patient medically ﬁt for surgery without signiﬁcant comorbidities
• Non-smoker
• Immediate or delayed reconstruction
• Unilateral reconstruction
• Patient unsuitable for or unwilling to accept major surgery involving abdominal
autologous tissue transfer
• Preference of autologous reconstruction over implant-based
Exclusion criteria
• Patient unable to give consent
• Presence of major medical conditions that may compromise patient's health
• Previous history of radiotherapy
• Presence of pacemaker or metallic prosthesis making patient unsuitable for MRI
• Body mass index b20 kg/m2
• Taking medication for weight loss at the time of baseline visit
239W.A. Morrison et al. / EBioMedicine 6 (2016) 238–245et al., 2013). However major hurdles persist in ensuring proper vascu-
larization of the construct following implantation (Post et al., 2013)
and this has limited the success of this approach to the engineering of
either thin or metabolically low-demanding tissues. In addition, the
scaffold-cell concept usually implies the extraction of cells from the pa-
tient, their processing andassembly into scaffolds in theatre ormore com-
monly in the laboratory, and subsequent surgical implantation. The safety
and ethical issues related to the ex vivomanipulation are further obstacles
to success. The second approach involves growing tissues directly in vivo
within a chamber space. When a vascular loop or pedicle is connected to
the host's circulation and inserted into the chamber spontaneous tissue
grows around the loop (Tanaka et al., 2000; Mian et al., 2000; Lokmic
et al., 2007). For tissue speciﬁcity this approach usually also requires
cues from the implantation of cells, scaffoldmatrices or growth factorma-
nipulation. The concept presented in this paper is based on the in vivo
chambermodel but is essentially different from the scaffold-cell paradigm
as it involves the stimulation of tissue growthdirectly in vivoby exploiting
the organism's regenerative capacity, without involving implantation of
cells, extracellular matrix or exogenous growth factors, therefore elimi-
nating concerns about ex vivo cell/tissue manipulation. In this sense, the
tissue-engineering chamber works as an internal bioreactor in which tis-
sue expands concomitantly with the development of a robust autologous
vascular network originating from the vascular pedicle (artery and vein)
inside the chamber. Unlike current techniques including fat grafting or
cell-based therapies, this approach is not focused towards creating an en-
vironment that supports survival of cells, but rather to expand existing
differentiated tissue by hypertrophy and hyperplasia, thus having the
potential of up scaling the engineering of tissues to large, thick, three-
dimensional, well-vascularized clinically relevant constructs. Previously,
we have reported this phenomenon in animals. Through different exper-
imental models we and others have demonstrated that when a fat ﬂap isTable 2
Patients' data. m:months; y: years; NIDDM: non-insulin dependent diabetes mellitus; WLE: wi
ferior gluteal artery perforator ﬂap.
Patient Age, y BMI (kg/m2) Comorbidities Time since
mastectomy
Adjuvant
therapy
Oncologi
1 35 21 None 42 m None SSM. Pre
defect aft
2 47 23 NIDDM (diet
controlled)
14 y None Simple m
3 44 20.1 None 6 m None Simple m
4 49 26.8 None 11 m Tamoxifen Simple m
5 48 22.4 None 12 m None SSM afteplaced inside a non-collapsible chamber, de novo well-vascularized
adipose tissue as large as 78.5 ml can be generated and remains stable
several weeks after chamber removal (Cronin et al., 2004; Dolderer
et al., 2007, 2011; Findlay et al., 2011; Zhan et al., 2015). We have
shown that inﬂammation is one of the key factors driving the gener-
ation of new tissue inside the chamber (Lilja et al., 2013). In addition,
the strong angiogenic sprouting from the vascular pedicle inside the
space and a mechanotransduction effect elicited by the stretch of tis-
sues after placing the chamber are very likely to be participating in
the process as well (Mian et al., 2000; Liu and Lee, 2014). In light of
the promising ﬁndings in animals, we hypothesized that the TEC
model might have a similar effect on tissue growth in the clinical
setting. Herein we present an upscale of our research into a clinical
trial providing “proof-of-concept” that adipose tissue engineering
using the chamber model is feasible in humans and that large
clinically relevant volumes of tissue can be generated.
2. Patients and Methods
This study was conducted under strict adherence to Australian
National Health and Medical Research Council ethics guidelines and
was approved by the Human Ethics Committee of St. Vincent's Hospital
Melbourne (Protocol # 156/08).
2.1. Study Design and Participants
To test our hypothesis in a situation of clinical relevance, women
candidates for breast reconstruction were selected according to criteria
listed in Table 1. Candidates were selected on the basis that autologous
tissue was unavailable, were not prepared to undergo major surgery
and wished to avoid silicone implants if possible. Those with a previous
history of radiotherapy were excluded from the trial selection criteria.
On recruitment, patients were informed that if the procedure failed to
generate sufﬁcient tissue, they would require a silicone implant. Addi-
tionally, patients were informed that as the chamber was as yet non-
biodegradable, a second stage removal procedure would be required.
Five patients were recruited, their details listed in Table 2. Written in-
formed consent was obtained from each patient after detailed explana-
tion of the whole procedure, its potential risks and beneﬁts.
2.2. Chamber Fabrication and Surgical Procedures
Dome-shaped, hollow, 3 mm thick perforated acrylic chambers
were custom-made ranging from 140 to 360 ml (Anatomics Pty
Ltd., Melbourne, Australia) ml to match each patient's contralateral
breast volume. An open notch at one point of the chamber rim was
incorporated to allow unimpeded access for the transposed vascular
pedicle of the thoracodorsal artery perforator (TAP) fat ﬂap (Fig. 1A).
To allow for the newly formed tissue to have maximum contact with
surrounding vascularized tissue and integrate with the chest wall,de local excision; SSM: skin-sparingmastectomy; DCIS: ductal carcinoma in situ; IGAP: in-
c surgery Side Previous reconstruction
sents with partial contour
er reconstruction
Left Initial immediate expander followed by implant
Infected implant replaced by free IGAP
astectomy Right Tissue expander ﬁlled to 260 cm3 10 months
earlier and removed at the time of chamber
insertion No implant exchange.
astectomy Right None
astectomy Right Tissue expander during trial 8 weeks prior to
chamber insertion
r WLE for DCIS Right Tissue expander during trial 8 weeks prior to
chamber insertion
Fig. 1.Chamber and surgical procedure. (A) Acrylic 210 cm3 chamberwith notchon one side to allow for pedicle passage. (B) Preoperativemarkings of thoracodorsal artery perforators and
TAP ﬂap design in patient 2. Tissue expander in place post right mastectomy. (C) Harvested fat ﬂap approximately 30 ml based on thoracodorsal system. (D) Flap transposed onto chest
wall with dome shaped chamber placed on top.
240 W.A. Morrison et al. / EBioMedicine 6 (2016) 238–245the chamber domesweremultiply perforated and they had no base. Two
patients had a tissue expander placed 8 weeks before to create sufﬁcient
space for the chamber. Preoperative markings of an ipsilateral TAP ﬂap
were made and the perforators located using handheld doppler (Fig.
1B). Under general anaesthesia, mastectomy scars and expanders
(whenpresent)were removed followed by capsulectomy andpocket dis-
section (subcutaneous or submuscular). Next, a TAP fat ﬂap ranging from
approximately 6 to 50 ml was harvested (Fig. 1C). The size was deter-
mined by taking into consideration fat availability and minimisation of
the donor defect. The ﬂapwas then tunnelled subcutaneously, and trans-
posed onto the chest wall as a nidus for tissue regeneration. The chamber
domewas inserted over the ﬂap and securedwith resorbable sutures en-
suring that the pedicle had easy passage through the notch (Fig. 1D). To
provide adequate coverage of the device, a submuscular plane was cho-
sen, except in patient 1 who had the chamber placed subcutaneously
for partial reconstruction. Drains were inserted and wounds were closed
in a standard fashion. No immediate postoperative complications were
registered and patients were discharged on postoperative day 3.Table 3
Magnetic resonance imaging ﬁndings. N/A: not available.
Patient 3 months
1 Disc-shaped fat ﬂap lying superﬁcial to pectoralis major with an approximate
volume of 12 ml
2 Fat ﬂap in upper outer quadrant of chamber with an approximate volume of
20 ml. There appears to be vascularization predominantly through the holes
of the chamber
3 N/A
4 Fat ﬂap with an approximate volume of 27 ml. There are small vessels within
the ﬂap coming from the axilla and also vessel branching from the chest wall
5 Flat discoid fat ﬂap within the chamber with a volume of
approximately 16 ml. Internal vessels are evident.2.3. Postoperative Evaluation and Chamber Removal
After the initial postoperative visit, all patients were initially follow-
ed at monthly intervals and then every three months after the third
month. Magnetic resonance imaging (MRI) was performed on each pa-
tient at three and six months postoperatively.
In accordance with study design, six months after placement, the
chambers were removed under general anaesthesia through the previ-
ousmastectomy incision. In one patient (patient 2) inwhom signiﬁcant
growth of tissue was observed onMRI, the chamber was left in place for
another six months by mutual agreement.2.4. Histological Analysis
Tissue samples were obtained at the time of chamber removal and
ﬁxed in parafﬁn. Immunostaining with perilipin and CD31 were then
performed.6 months
No increase in ﬂap growth. Evidence of well vascularized fat tissue corresponding
to the ﬂap
Expansion of ﬂap volume with vessels invading it via the holes of the chamber
N/A
Compared to previous study, there appears to have been some contraction of the
fat ﬂap with slight decrease of volume predominantly due to ﬂattening
Compared to previous study, there has been little growth of the fat ﬂap, less than
3 mm in cross sectional diameter The architecture is similar
Fig. 2. Intraoperative viewuponchamber removal of patient 2. The 210ml space is entirely
ﬁlled with tissue. (A) Oblique lateral view. (B) Frontal view.
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No complications such as infection, device exposure, hematoma
or seroma were observed throughout the trial. All patients, except
one (patient 3), tolerated the chamber adequately with early low-
grade pain that resolved spontaneously without any further inter-
ventions. After chamber removal, all patients recovered uneventful-
ly. MRI ﬁndings are summarized in Table 3. Flap and chamber details
are summarized in Table 4. In patient 2, MRI at six months showed
ﬂap enlargement, so she was offered the opportunity to keep the
chamber in place for another six months to allow for further growth.
At 12 months, the chamber was removed and the 210 ml space was
ﬁlled with tissue in its entirety (Fig. 2). While the tissue in the lateral
component (i.e. next to the pedicle) had a macroscopic appearance
and palpable texture very similar to that of native fat (Fig. 3), tissue
in the medial aspect was ﬁrmer and looked more ﬁbrotic. When
punctured, all regions of the newly formed tissue bled, showing
good vascularization of the construct. Encapsulation around the ex-
terior of the chamber caused the ﬂap to be embedded into a thick
wall resulting in a ﬂattening effect and reduced projection compared
with the immediate post implantation appearance. Even though the
ﬁnal volume did not completely match the opposite breast, a deci-
sion was made not to insert an implant. At six months follow-up
the tissue remained stable and had softened to a “fat-like” consisten-
cy (Fig. 4). Patient 3, who had the lowest body mass index of the co-
hort and consequently received the smallest chamber (140 ml), had
the chamber removed at 7 weeks due to continuous pain from rub-
bing of the chamber rim over her rib at one point. Upon removal,
the cavity was approximately half full of ﬂimsy, haemovascular and
ﬁbrous adipose-like tissue. Once the “thread-like” tissue projections
into the chamber holes were released, the tissue compacted to an es-
timated volume of 25 ml, which was roughly four times that of the
original ﬂap (6 ml). The piece was removed en-bloc and sent for his-
tological analysis, showing viable fat containing perfused blood ves-
sels (Fig. 5). A silicone implant was inserted and the postoperative
course was unremarkable. Patients 1, 4 and 5 failed to grow tissue
beyond the initial ﬂap's dimensions. On exploration at six months,
their chambers were densely encapsulated and embedded into the
pectoral muscle. Upon removal, a thick ﬁbrous capsule covering the
ﬂap and compressing it into a discoid ﬂat patch was observed (Fig.
6). Histological analysis of these specimens using perilipin and
CD31 staining revealed the presence of viable well-vascularized fat
inside the chamber (Fig. 7). Reconstruction in these cases was car-
ried out with silicone implants, without further complications.4. Discussion
The ability to generate signiﬁcant volumes of soft tissue resembling
(or equal to) fat for clinical purposes would certainly have an impact on
regenerative medicine. Donor site-derived issues, alloplastic-related
complications and the unpredictability of fat grafting would all be ad-
dressed and eliminated, should an autologous, stable, soft, pliable, well
vascularized engineered tissue become available.Table 4
Chamber and ﬂap details and summary of intraoperative ﬁndings upon chamber removal.
Patient Chamber
volume (cc)
Approximate ﬂap
volume (ml)
Plane of insertion
1 150 12 Subcutaneous
2 210 30 Submuscular
3 140 6 Submuscular
4 360 50 Submuscular
5 250 30 SubmuscularThe traditional paradigm of tissue engineering is based on the use of
scaffolds and cells in different combinations to create tissues or enhance
their growth. First-in-human studies have used this approach for the re-
pair of tissues such as the bladder, vaginal vault, blood vessels, and nasal
nostril (Atala et al., 2006; Raya-Rivera et al., 2014; Fulco et al., 2014;
Olausson et al., 2012). Although attractive, we cannot rush into thinking
that this approach can be readily applied to the engineering of other im-
portant tissues such as muscle or fat. The bladder wall, vaginal wall and
cartilage are tissues either thin enough to rely on nutrient diffusion until
neo-vascularization occurs or with a low metabolic rate that allows
them to survive under hypoxic conditions. By contrast, a 210ml volume
of adipose tissue is a different challenge. Due to its thickness, dimen-
sions andmetabolic requirements, such a block of tissue needs a reliable
source of blood supply from the beginning. This is achieved with the
TEC: growth and expansion of tissue concomitantly with angiogenesis
and the development of a reliable vasculature. This ﬁrst-in-humanRemoval Intraoperative ﬁndings
6 months No signiﬁcant growth. Thick ﬁbrous capsule covering ﬂap
12 months Chamber entirely ﬁlled with tissue, which is soft and
pliable in the lateral aspect and more ﬁbrotic medially
7 weeks Chamber removed early because of pain. Haemovascular
adipose-like tissue approximately 4 times original ﬂap volume
6 months Flap encased in a thick overlying ﬁbrous capsule
6 months Flap encased in a thick overlying ﬁbrous capsule
Fig. 3.Detail of tissue generated in patient 2 showing adipose tissue under ﬁbrous capsule
in the lateral aspect.
242 W.A. Morrison et al. / EBioMedicine 6 (2016) 238–245pilot study represents an important upscale in the research and clinical
application of tissue engineering, as it reports on the largest block of
well differentiated vascularized tissue grown so far. Birchall and
Seifalian in their Comment published in Lancet in 2014 pose the impor-
tant question: Is it possible to scale up the volume of organs and tissues
replaced using tissue-engineering technologies? (Birchall and Seifalian,
2014) We believe that such upscale is indeed achievable and that the
TEC may hold promise for the development and growth of sizeable tis-
sues and organs. In the current trial we have tested the chamber in aFig. 4. Patient 2 after chamber removal. (A) Immediate postoperative result. (B) Six
months follow-up. Newly grown tissue remained stable and had softened to a “fat-like”
consistency.
Fig. 5. (A) Specimen excised from patient 3 after formalin ﬁxation. Note that in spite of
early chamber removal (7 weeks), approximately a four-fold increase in tissue volume
is observed. (B) Histological analysis showing viable adipose tissue as demonstrated by
perilipin staining.breast reconstruction setting, which is a fairly standardized model for
soft tissue reconstruction. By nomeans the tissue-engineering chamber
is speciﬁcally devised as an alternative to breast restoration but offers a
solution for soft tissue defects elsewhere in the body as well as for the
generation of tissues other than fat. In fact, using the TEC model, our
group has been able to grow functional specialized tissues such as
heart, thymus and liver, albeit with the inclusion of speciﬁc cell types
(Morritt et al., 2007; Seach et al., 2010; Forster et al., 2011). Despite
the unquestionable observation that human tissue did grow inside the
chamber, the difference in the consistency of results compared with
those obtained in animals needs further investigation. One clear differ-
ence is that small animals and pigs continue to grow throughout life
and during the experiment, whilstmature human tissue is homeostatic.
Additionally, wounds in animals are made de novowhereas in patients
scarring from previous surgeries, might affect the tissues' vasculariza-
tion and growth potential.
The exactmechanismsdriving the formation of new tissue inside the
chamber remain to be fully elucidated.When the chamber is placed, the
tissues are inevitably stretched generating traction forces that are trans-
mitted to the tissue inside the chamber through the shell perforations.
By the phenomenon of mechanotransduction (Liu and Lee, 2014),
these forces may very likely stimulate cell proliferation, migration and
differentiation (Heit et al., 2012). In addition, after implantation, intra-
chamber edema (ﬂuid accumulation) ensues; previous authors have al-
ready suggested that edema stimulates adipogenesis (Brorson, 2004).
Also, an angiogenic response and sprouting from the vascular pedicle
Fig. 6. Intraoperative view upon chamber removal of patient 4. After removing the
chamber, the space was empty, being ﬂuid ﬁlled only, and the fat ﬂap was seen to be
encased in a thick ﬁbrotic capsule without signs of enlargement (A). After capsulectomy,
a healthy normal-looking adipose tissue ﬂap was observed (B).
Fig. 7. Histological analysis of encased fat excised in patient 4. (A) Perilipin staining
conﬁrms viability of adipose tissue under the ﬁbrous capsule. (B) CD31 staining shows
adipocytes surrounding perfused blood vessels.
243W.A. Morrison et al. / EBioMedicine 6 (2016) 238–245is elicited by the chamber through a dual effect: by promoting an ische-
mic environment inside the newly created non-collapsible space and by
stretching the overlying tissues. Both ischemia and tissue strain have
been shown to enhance angiogenesis and result in a signiﬁcant increase
in blood vessel density (Huang et al., 2014). Considering that vasculari-
zation is a key aspect of tissue growth, these two phenomena surely
play a fundamental role in the generation of new tissue inside the
chamber. Furthermore, the surgical trauma generates an inﬂammatory
stimulus that attracts macrophages and mesenchymal stem, which or-
chestrate a reparative/regenerative process. In previous experiments
we have observed that inﬂammation, through an array of cytokines
and chemoattractants including monocyte chemotactic protein-1
(MCP-1), TNF-α and Interleukin 1-ß, is an important step in adipogen-
esis inside the tissue-engineering chamber (Lilja et al., 2013). Lastly, the
fact that patient 2 was a diabetic, might also have had an inﬂuence on
the growth of tissue inside her chamber. There is evidence that diabetic
patients have increased levels of circulating dickkopf-1 a potent inhibi-
tor of theWnt/ß-catenin signalling pathway (Lattanzio et al., 2014). In-
hibition of this pathway has been regarded as an important step in the
commitment of stem cells to pre-adipocytes, which eventually undergo
full differentiation to functioning adipocytes (D'Alimonte et al., 2013;
Ross et al., 2000).
There are several advantages of using the TEC model in humans,
such as the elimination of ex vivo tissue manipulation, the avoidance
of exogenous growth factors, which is paramount when dealing with
cancer-related defects, and the fact that it is well tolerated and has a
close resemblance to the insertion of a silicone implant. However, the
fact that a signiﬁcant amount of tissue was obtained in only one of the
four patients who completed the trial calls for the identiﬁcation of cur-
rent ﬂaws and potential improvements. One of the limiting factors for
the non-successful cases seemed to be the development of a thick ﬁ-
brous capsule that prevented expansion and growth of the ﬂap. The re-
duction of such a capsule using antiﬁbrotic and/or anti-inﬂammatoryagents is therefore a potential target of improvement (DiEgidio et al.,
2014). Strategies to engineer the biomaterial surfaces and/or incorpo-
rate slowly releasing anti-inﬂammatory molecules to reduce possible
in vivo reactions to the chamber itself may also be beneﬁcial (Go et al.,
2015; Croll et al., 2006). Another hypothetical strategy that might im-
prove the current model is the creation of a more adipogenic environ-
ment both inside and outside the chamber by: 1) enhancing the
surrounding vascularity; 2) adding stromal vascular fraction (SVF) or
ASCs; and 3) adding an adipogenic scaffold or matrix to stimulate ﬂap
growth (Ting et al., 2014; Poon et al., 2013).
Adequate blood supply is critical for survival of any engineered
tissue. Several studies have investigated the close relationship that
exists between angiogenesis and adipogenesis (Cao, 2007; Rophael
et al., 2007; Hutley et al., 2001). Our previous research has shown
that the vascular stimulus that drives tissue growth is derived not
only from the pedicle but also from the surrounding tissues outside
the chamber (Cronin et al., 2004). Hence, the presence (or the crea-
tion) of a better vascularized environment prior to chamber implan-
tation might turn out to be more conducive of adipogenesis and
tissue growth. In this sense, the BRAVA ® system described by
Khouri might serve as an enhancer of our chamber model (Khouri
et al., 2015). The mechanical traction generated by the device not
only creates a virtual space but also elicits a profound angiogenic
and adipogenic response (Lujan-Hernandez et al., 2016). Thus, it is
possible that by pre-conditioning the recipient site through external
mechanical traction, a more robust growth of the fat ﬂap inside the
244 W.A. Morrison et al. / EBioMedicine 6 (2016) 238–245chamber can be obtained. Multi operations in patients 1 and 5 might
have reduced their tissues' vascularity and their ability to support
expansion of the ﬂap, in contrast to patient 2 and 3who had a history
of one previous surgery only. In patient 3, despite the early chamber
removal, the volume of the ﬂap was fourfold the original. Patient 4
was similar to 2 and 3 in terms of history of prior surgeries, however,
at the time of chamber insertion and throughout the whole trial, she
was taking tamoxifen, which has been recently shown to inhibit
ASCs' proliferation and differentiation rate and is associated with de-
creased fat graft survival (Pike et al., 2015).
SVF and ASCs could be considered important enhancers of growth in
our currentmodel. Ex vivo expandedASCs could potentially improve tis-
sue growth in a way similar to that reported by Kølle et al. (Kølle et al.,
2013). However, despite the reported advantages of using SVF/ASCs to
enhance fat grafting, there are oncological matters that need to be fur-
ther investigated before translation into human tissue engineering, as
adipose-derived mesenchymal stem cells and adipocytes may promote
progression and metastatic spread in breast cancer and melanoma
(Rowan et al., 2014; Kwan et al., 2014).
The presence of a scaffold or matrix with an adipogenic potential
able to stimulate and guide tissue growth inside the chamber could
also result in a greater expansion of the ﬂap (Ting et al., 2014; Poon
et al., 2013; Wittmann et al., 2015). Additionally, a cell-homing effect
for adipose and endothelial precursors by modulating the stromal-
derived factor (SDF)-1/CXCR4 axis could eventually lead to a more con-
sistent growth of theﬂap inside the chamber, though notwithout risk of
cancer induction (Xu et al., 2014).
The remarkable advances in adipose tissue engineering are paving
the way towards its successful clinical application. The results of this
trial provide clinical evidence on the largest well-vascularized block of
engineered tissue ever used in humans, along with “proof-of-concept”
that generation of adipose tissue using the chamber model is clinically
feasible. Undoubtedly, there are several aspects that need to be im-
proved, and further research is warranted before deﬁnitive translation
onto the clinical setting is achieved; nevertheless we believe that this
report represents an important step forward on the road to human ad-
ipose tissue engineering, which is seemingly not far from reach.Disclosure
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